SK4642000A3 - Pharmaceutical composition containing liposomal encapsulated taxane and its antineoplastic derivative - Google Patents

Pharmaceutical composition containing liposomal encapsulated taxane and its antineoplastic derivative Download PDF

Info

Publication number: SK4642000A3
Authority: SK; Slovakia
Prior art keywords: pharmaceutical composition; taxane; administration; dose; intended
Prior art date: 1998-07-01

Application number

SK464-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Aquilar Rahman

Original Assignee

Neopharm

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-01

Filing date

1999-06-29

Publication date

2000-11-07

1999-06-29 Application filed by Neopharm filed Critical Neopharm

2000-11-07 Publication of SK4642000A3 publication Critical patent/SK4642000A3/sk

Links

229940123237 Taxane Drugs 0.000 title claims abstract description 57
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title claims abstract description 50
230000000118 anti-neoplastic effect Effects 0.000 title claims abstract description 6
239000008194 pharmaceutical composition Substances 0.000 title claims description 31
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 41
229930012538 Paclitaxel Natural products 0.000 claims abstract description 39
229960001592 paclitaxel Drugs 0.000 claims abstract description 39
239000000203 mixture Substances 0.000 claims abstract description 27
206010028980 Neoplasm Diseases 0.000 claims abstract description 12
231100000419 toxicity Toxicity 0.000 claims abstract description 11
230000001988 toxicity Effects 0.000 claims abstract description 11
239000002502 liposome Substances 0.000 claims description 26
238000001802 infusion Methods 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 16
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 15
238000011282 treatment Methods 0.000 claims description 10
231100000226 haematotoxicity Toxicity 0.000 claims description 9
208000003455 anaphylaxis Diseases 0.000 claims description 6
231100000371 dose-limiting toxicity Toxicity 0.000 claims description 6
206010033128 Ovarian cancer Diseases 0.000 claims description 5
229940125715 antihistaminic agent Drugs 0.000 claims description 5
239000000739 antihistaminic agent Substances 0.000 claims description 5
206010002198 Anaphylactic reaction Diseases 0.000 claims description 4
206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
-1 t-acetylpaclitaxel Chemical compound 0.000 claims description 3
TYLVGQKNNUHXIP-MHHARFCSSA-N 10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 TYLVGQKNNUHXIP-MHHARFCSSA-N 0.000 claims description 2
206010006187 Breast cancer Diseases 0.000 claims description 2
206010009944 Colon cancer Diseases 0.000 claims description 2
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
208000029742 colonic neoplasm Diseases 0.000 claims 1
238000007912 intraperitoneal administration Methods 0.000 claims 1
238000001990 intravenous administration Methods 0.000 claims 1
201000005202 lung cancer Diseases 0.000 claims 1
208000020816 lung neoplasm Diseases 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
238000009101 premedication Methods 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
238000000034 method Methods 0.000 abstract description 19
201000011510 cancer Diseases 0.000 abstract description 9
230000000694 effects Effects 0.000 abstract description 4
229940079593 drug Drugs 0.000 description 13
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 11
239000002904 solvent Substances 0.000 description 11
230000000259 anti-tumor effect Effects 0.000 description 8
150000002632 lipids Chemical class 0.000 description 7
210000004185 liver Anatomy 0.000 description 7
241000282412 Homo Species 0.000 description 6
235000012000 cholesterol Nutrition 0.000 description 6
238000009472 formulation Methods 0.000 description 6
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
241000124008 Mammalia Species 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
206010020751 Hypersensitivity Diseases 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102000029749 Microtubule Human genes 0.000 description 3
108091022875 Microtubule Proteins 0.000 description 3
206010030216 Oesophagitis Diseases 0.000 description 3
229940087168 alpha tocopherol Drugs 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
208000006881 esophagitis Diseases 0.000 description 3
230000002489 hematologic effect Effects 0.000 description 3
210000004688 microtubule Anatomy 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
239000008389 polyethoxylated castor oil Substances 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
229960000984 tocofersolan Drugs 0.000 description 3
239000002076 α-tocopherol Substances 0.000 description 3
235000004835 α-tocopherol Nutrition 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
206010013975 Dyspnoeas Diseases 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
231100000682 maximum tolerated dose Toxicity 0.000 description 2
238000002156 mixing Methods 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000002691 unilamellar liposome Substances 0.000 description 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
206010048610 Cardiotoxicity Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
208000000616 Hemoptysis Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000007650 Meningeal Carcinomatosis Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000002052 anaphylactic effect Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
231100000457 cardiotoxic Toxicity 0.000 description 1
230000005928 cardiotoxic reaction Effects 0.000 description 1
231100000259 cardiotoxicity Toxicity 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
231100001156 grade 3 toxicity Toxicity 0.000 description 1
231100000171 higher toxicity Toxicity 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000008206 lipophilic material Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000036457 multidrug resistance Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
VZUGBLTVBZJZOE-KRWDZBQOSA-N n-[3-[(4s)-2-amino-1,4-dimethyl-6-oxo-5h-pyrimidin-4-yl]phenyl]-5-chloropyrimidine-2-carboxamide Chemical compound N1=C(N)N(C)C(=O)C[C@@]1(C)C1=CC=CC(NC(=O)C=2N=CC(Cl)=CN=2)=C1 VZUGBLTVBZJZOE-KRWDZBQOSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000012106 negative regulation of microtubule depolymerization Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
238000009512 pharmaceutical packaging Methods 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000113 radiomimetic effect Effects 0.000 description 1
239000002683 reaction inhibitor Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
238000000527 sonication Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
150000004579 taxol derivatives Chemical class 0.000 description 1
SDCJNZZAOLRVCP-GTOSQJSUSA-N tetramyristoyl cardiolipin Chemical compound CCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCC)COP(O)(=O)OCC(O)COP(O)(=O)OC[C@H](OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC SDCJNZZAOLRVCP-GTOSQJSUSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dispersion Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

SK464-2000A 1998-07-01 1999-06-29 Pharmaceutical composition containing liposomal encapsulated taxane and its antineoplastic derivative SK4642000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/108,509 US6146659A (en)	1998-07-01	1998-07-01	Method of administering liposomal encapsulated taxane
PCT/US1999/014986 WO2000001366A1 (en)	1998-07-01	1999-06-29	A method of administering liposomal encapsulated taxane

Publications (1)

Publication Number	Publication Date
SK4642000A3 true SK4642000A3 (en)	2000-11-07

Family

ID=22322617

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK464-2000A SK4642000A3 (en)	1998-07-01	1999-06-29	Pharmaceutical composition containing liposomal encapsulated taxane and its antineoplastic derivative

Country Status (17)

Country	Link
US (1)	US6146659A (de)
EP (1)	EP1009384A4 (de)
JP (2)	JP2001524990A (de)
KR (1)	KR20010023522A (de)
CN (1)	CN1275076A (de)
AU (1)	AU730599B2 (de)
BR (1)	BR9906581A (de)
CA (1)	CA2301057C (de)
EA (1)	EA003678B1 (de)
HU (1)	HUP0004583A3 (de)
IL (1)	IL134747A0 (de)
NO (1)	NO20001012L (de)
NZ (1)	NZ524490A (de)
PL (1)	PL338951A1 (de)
SK (1)	SK4642000A3 (de)
TR (1)	TR200000576T1 (de)
WO (1)	WO2000001366A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030087954A1 (en) *	1997-01-07	2003-05-08	Sonus Pharmaceuticals, Inc.	Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US6458373B1 (en) *	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US7112338B2 (en) *	1997-03-12	2006-09-26	The Regents Of The University Of California	Cationic liposome delivery of taxanes to angiogenic blood vessels
US7262173B2 (en) *	1997-03-21	2007-08-28	Georgetown University	Chemosensitizing with liposomes containing oligonucleotides
US8853260B2 (en)	1997-06-27	2014-10-07	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6461637B1 (en) *	2000-09-01	2002-10-08	Neopharm, Inc.	Method of administering liposomal encapsulated taxane
US7314637B1 (en) *	1999-06-29	2008-01-01	Neopharm, Inc.	Method of administering liposomal encapsulated taxane
US6835721B2 (en) *	1999-02-01	2004-12-28	Eisai Co., Ltd.	Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) *	1999-02-01	2004-01-08	Hawkins Lynn D.	Immunomodulatory compounds and method of use thereof
US7915238B2 (en) *	1999-02-01	2011-03-29	Eisai R & D Management Co., Ltd.	Immunomodulatory compounds and methods of use thereof
USRE43914E1 (en) *	1999-06-09	2013-01-08	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention	Method for detecting syphilis using synthetic antigens
KR100591767B1 (ko) *	1999-09-09	2006-06-23	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	탁산의 맥관형성 혈관 전달을 위한 양이온성 리포좀
CO5280224A1 (es) *	2000-02-02	2003-05-30	Univ Florida State Res Found	Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
DE60123583T2 (de) *	2000-02-04	2007-08-09	Lipoxen Technologies Ltd.	Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
US20030133972A1 (en) *	2000-10-11	2003-07-17	Targesome, Inc.	Targeted multivalent macromolecules
US20030129223A1 (en) *	2000-10-11	2003-07-10	Targesome, Inc.	Targeted multivalent macromolecules
EP1355634B8 (de)	2000-11-09	2009-03-04	Neopharm, Inc.	Sn-38-lipidkomplexe und verfahren zu ihrer verwendung
US20020073441A1 (en)	2000-12-13	2002-06-13	Ross Brian D.	Compositions and methods for detecting proteolytic activity
WO2003030864A1 (en) *	2001-05-29	2003-04-17	Neopharm, Inc.	Liposomal formulation of irinotecan
CA2354486A1 (en) *	2001-07-31	2003-01-31	Florida State University Research Foundation, Inc.	C7 ester substituted taxanes
WO2003018018A2 (en) *	2001-08-24	2003-03-06	Neopharm, Inc.	Vinorelbine compositions and methods of use
DE10154464B4 (de) *	2001-11-08	2005-10-20	Max Delbrueck Centrum	Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
EA200400658A1 (ru) *	2001-11-09	2004-10-28	Неофарм, Инк.	Способ лечения опухолей, экспрессирующих рецептор для ил-13 (варианты)
US20030236301A1 (en) *	2001-12-19	2003-12-25	Bob Sanders	Liposomal delivery of vitamin E based compounds
US20030180348A1 (en) *	2002-03-22	2003-09-25	Levinson R. Saul	Transcellular drug delivery system
US7138512B2 (en) *	2002-04-10	2006-11-21	Georgetown University	Gene SHINC-2 and diagnostic and therapeutic uses thereof
CN101134119A (zh)	2002-05-24	2008-03-05	血管技术国际股份公司	用于涂覆医用植入物的组合物和方法
WO2003102011A1 (en) *	2002-05-29	2003-12-11	Neopharm, Inc.	Method for determining oligonucleotide concentration
ATE424187T1 (de) *	2002-07-15	2009-03-15	Alcon Inc	Bioerodierbare folie zur abgabe eines ophthalmischen arzneimittels
KR100533458B1 (ko)	2002-07-20	2005-12-07	대화제약 주식회사	파클리탁셀의 가용화용 조성물 및 그의 제조 방법
AU2003268087A1 (en) *	2002-08-23	2004-03-11	Ian Ma	Liposomal gemcitabine compositions for better drug delivery
BRPI0407096A (pt) *	2003-02-03	2006-01-24	Neopharm Inc	Taxano encapsulado em lipossomo estável, estéril e filtrável e outros fármacos antineoplásicos
EA200501285A1 (ru) *	2003-02-11	2006-02-24	Неофарм, Инк.	Способ получения липосомальных препаратов
WO2004087758A2 (en) *	2003-03-26	2004-10-14	Neopharm, Inc.	Il 13 receptor alpha 2 antibody and methods of use
EP1643971A2 (de) *	2003-05-22	2006-04-12	Neopharm, Inc.	Liposomale formulierungen mit einer kombination aus zwei oder mehr wirkstoffen
US20060078560A1 (en) *	2003-06-23	2006-04-13	Neopharm, Inc.	Method of inducing apoptosis and inhibiting cardiolipin synthesis
WO2005039533A1 (en) *	2003-10-15	2005-05-06	Medigene Ag	Method of administering cationic liposomes comprising an active drug
EP1737444A4 (de)	2004-03-05	2008-05-21	Univ Florida State Res Found	C7-lactyloxa-substituierte taxane
EP2407169A1 (de) *	2004-04-22	2012-01-18	Celator Pharmaceuticals, Inc.	Kombinationsformulierungen aus Anthracyclinwirkstoffen und Cytidinanaloga
JP4433918B2 (ja) *	2004-07-15	2010-03-17	コニカミノルタエムジー株式会社	画像形成方法
MX2007005234A (es) *	2004-10-29	2008-03-10	Neopharm Inc	Proceso de fabricacion para preparaciones liposomales.
EP1827395A2 (de)	2004-11-02	2007-09-05	Tel-Aviv University Future Technology Development L.P.	Formulierungen von wasserunlöslichen oder schwer wasserlöslichen arzneimitteln in lipidierten glykosaminoglykanpartikeln, deren herstellung und deren verwendung zur diagnose und therapie
KR100651728B1 (ko) *	2004-11-10	2006-12-06	한국전자통신연구원	정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
CN103285392A (zh)	2005-04-26	2013-09-11	卫材R&D管理株式会社	用于癌症免疫疗法的组合物和其用途
US20070292418A1 (en) *	2005-04-26	2007-12-20	Eisai Co., Ltd.	Compositions and methods for immunotherapy
EP1896007B1 (de)	2005-05-04	2014-03-19	Medigene AG	Verfahren zur verabreichung einer katonischen zubereitung aus liposomen, welche paclitaxel enthält
BRPI0709075A2 (pt)	2006-03-20	2011-10-11	Medigene Ag	tratamento de cáncer de mama triplo receptor negativo
EP2010150A2 (de) *	2006-04-20	2009-01-07	Amgen Inc.	Stabile emulsionsformulierungen
JP2010509355A (ja)	2006-11-06	2010-03-25	ジャイナファーマシューティカルズ，インコーポレーテッド	グッグルリン脂質の方法および組成物
GB0905348D0 (en)	2009-03-27	2009-05-13	Ucl Business Plc	Carrier
US20110070294A1 (en) *	2009-09-23	2011-03-24	Javeri Indu	Methods for the Administration of Drugs Using Liposomes
US10143652B2 (en)	2009-09-23	2018-12-04	Curirx Inc.	Methods for the preparation of liposomes
CA2781527C (en) *	2009-09-23	2017-10-24	Indu Javeri	Methods for the preparation of liposomes
PL226015B1 (pl) *	2011-03-03	2017-06-30	Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną	Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
US10188728B2 (en)	2012-12-12	2019-01-29	Temple University—Of the Commonwealth System of Higher Education	Compositions and methods for treatment of cancer
WO2014165829A2 (en) *	2013-04-05	2014-10-09	Igdrasol	Nanoparticle formulations
CA2922002A1 (en)	2013-09-13	2015-03-19	Arbor Therapeutics, LLC	Nanoparticulate compositions for targeted delivery of lipophilic drugs and acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4861580A (en) *	1985-10-15	1989-08-29	The Liposome Company, Inc.	Composition using salt form of organic acid derivative of alpha-tocopheral
US4812314A (en) *	1986-02-24	1989-03-14	Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization	Lipid replacement therapy
US4927571A (en) *	1987-05-18	1990-05-22	Liposome Technology, Inc.	Preparation of injectable doxorubicin/liposome suspension
ATE194767T1 (de) *	1992-03-23	2000-08-15	Univ Georgetown	In liposomen verkapseltes taxol und verwendungsverfahren
WO1994026254A1 (en) *	1993-05-17	1994-11-24	The Liposome Company, Inc.	Incorporation of taxol into liposomes and gels
JPH06329533A (ja) *	1993-05-20	1994-11-29	Kyowa Hakko Kogyo Co Ltd	リポソーム製剤の製造法
US5415869A (en) *	1993-11-12	1995-05-16	The Research Foundation Of State University Of New York	Taxol formulation
DE4430593C2 (de) *	1994-08-20	1999-01-14	Max Delbrueck Centrum	Verfahren zur Herstellung von Liposomal verkapseltem Taxol
DE69528077T2 (de) *	1994-11-18	2003-04-17	Aphios Corp., Woburn	Verfahren zur Herstellung von Liposomen, die hydrophobische Artzneistoffe enthalten
US5580899A (en) *	1995-01-09	1996-12-03	The Liposome Company, Inc.	Hydrophobic taxane derivatives
ATE309235T1 (de) *	1995-09-12	2005-11-15	Zeneus Pharma Ltd	Hydrolyse-einleitende hydrophobe taxane derivate
US5756537A (en) *	1996-11-08	1998-05-26	Parkash S. Gill, M.D., Inc.	Regime for paclitaxel in Kaposi's sarcoma patients

1998
- 1998-07-01 US US09/108,509 patent/US6146659A/en not_active Expired - Lifetime
1999
- 1999-06-29 EP EP99935394A patent/EP1009384A4/de not_active Withdrawn
- 1999-06-29 KR KR1020007002168A patent/KR20010023522A/ko not_active Ceased
- 1999-06-29 TR TR2000/00576T patent/TR200000576T1/xx unknown
- 1999-06-29 PL PL99338951A patent/PL338951A1/xx unknown
- 1999-06-29 SK SK464-2000A patent/SK4642000A3/sk unknown
- 1999-06-29 CN CN99801424A patent/CN1275076A/zh active Pending
- 1999-06-29 WO PCT/US1999/014986 patent/WO2000001366A1/en not_active Ceased
- 1999-06-29 NZ NZ524490A patent/NZ524490A/en unknown
- 1999-06-29 IL IL13474799A patent/IL134747A0/xx unknown
- 1999-06-29 EA EA200000282A patent/EA003678B1/ru not_active IP Right Cessation
- 1999-06-29 AU AU50880/99A patent/AU730599B2/en not_active Ceased
- 1999-06-29 CA CA002301057A patent/CA2301057C/en not_active Expired - Fee Related
- 1999-06-29 HU HU0004583A patent/HUP0004583A3/hu unknown
- 1999-06-29 JP JP55462599A patent/JP2001524990A/ja active Pending
- 1999-06-29 BR BR9906581-9A patent/BR9906581A/pt not_active Application Discontinuation
2000
- 2000-02-29 NO NO20001012A patent/NO20001012L/no not_active Application Discontinuation
2003
- 2003-07-16 JP JP2003197879A patent/JP2004059590A/ja active Pending

Also Published As

Publication number	Publication date
PL338951A1 (en)	2000-12-04
HUP0004583A2 (hu)	2001-08-28
AU5088099A (en)	2000-01-24
CN1275076A (zh)	2000-11-29
TR200000576T1 (tr)	2000-11-21
US6146659A (en)	2000-11-14
KR20010023522A (ko)	2001-03-26
EP1009384A1 (de)	2000-06-21
CA2301057C (en)	2009-03-10
NO20001012D0 (no)	2000-02-29
HUP0004583A3 (en)	2002-04-29
EP1009384A4 (de)	2004-11-17
BR9906581A (pt)	2000-09-26
IL134747A0 (en)	2001-04-30
NO20001012L (no)	2000-03-15
AU730599B2 (en)	2001-03-08
JP2001524990A (ja)	2001-12-04
CA2301057A1 (en)	2000-01-13
EA200000282A1 (ru)	2000-10-30
WO2000001366A1 (en)	2000-01-13
JP2004059590A (ja)	2004-02-26
EA003678B1 (ru)	2003-08-28
NZ524490A (en)	2005-04-29

Publication	Publication Date	Title
SK4642000A3 (en)	2000-11-07	Pharmaceutical composition containing liposomal encapsulated taxane and its antineoplastic derivative
US20050202074A9 (en)	2005-09-15	Method of administering liposomal encapsulated taxane
US5683715A (en)	1997-11-04	Taxane-containing phosphatidylcholine liposomes
US20030219476A1 (en)	2003-11-27	Liposomal formulation of mitoxantrone
Cabanes et al.	1998	Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel.
CN101138550B (zh)	2012-06-27	多种表面活性剂联合使用制备的混合胶束药物制剂及其制备方法
US20050249795A1 (en)	2005-11-10	Gemcitabine compositions for better drug delivery
WO2011038278A2 (en)	2011-03-31	Micelle encapsulation of therapeutic agents
DE60025494T2 (de)	2006-07-27	Epothilon zusammensetzungen
JP2006510674A (ja)	2006-03-30	脂質：エモジン製剤に関する組成物および方法
EP1435231B1 (de)	2009-12-30	Nicht-pegylierte lang-zirkulierende Liposome
WO2003105765A2 (en)	2003-12-24	Phospholipid micelles in liposomes as solubilizers for water-insoluble compounds
US7314637B1 (en)	2008-01-01	Method of administering liposomal encapsulated taxane
WO2004069224A2 (en)	2004-08-19	Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs
US20040228911A1 (en)	2004-11-18	Vinorelbine compositions and methods of use
WO2001070220A1 (en)	2001-09-27	A method of administering liposomal encapsulated taxane
MXPA00002170A (en)	2001-12-13	A method of administering liposomal encapsulated taxane
CZ20001046A3 (cs)	2000-08-16	Farmaceutická kompozice obsahující taxan
CN103025323A (zh)	2013-04-03	难溶性三环衍生物化合物的溶解度得到提高的药学组合物
ZA200100454B (en)	2002-12-24	A method of administering liposomal encapsulated taxane.
PL197938B1 (pl)	2008-05-30	Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna